ERBB2 and breast carcinoma: Identification of well-known biomarkers, e.g., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), all of which are molecular targets of therapeutic agents, have achieved good outcomes in terms of survival and treatment of breast cancer patients.